Odyssey
  • Homepage
  • Objectives
  • News
  • Publications
  • Privacy
    • Privacy Policy
    • Cookie Policy
  • Contact
Select Page

Search

results

Search

Results

Dolutegravir-Based ART is Superior to Standard of Care in Young Children Living With HIV (combined results of the main trial and the ‘under 14kg’ cohort)

Authors: Anna Turkova on behalf of the ODYSSEY trial team Presented at: CHIVA 2021 (Oral presentation) Download

read more

Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)

Authors: Turkova A on behalf of the ODYSSEY trial team      Presented at: CHIVA 2021   Read

read more

Virological failures and genotypic resistance in children and adolescents randomised to dolutegravir-based ART vs. standard-of-care in the main ODYSSEY trial (≥14kg)

Authors: White E and Kityo C on behalf of the ODYSSEY trial team Presented at: CHIVA 2021   Read

read more

This study is funded by ViiV Healthcare and the sponsor is Penta Foundation